Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance

Seminars in Hematology

Volumn 48, Issue 1, 2011, Pages 46-54

  Kristinsson, Sigurdur Yngvi ^a   Björkholm, Magnus ^a   Schulman, Sam ^a,b   Landgren, Ola ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MCMASTER UNIVERSITY   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ANTHRACYCLINE; BLOOD CLOTTING FACTOR 5 LEIDEN; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; FONDAPARINUX; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; PROTHROMBIN; THALIDOMIDE; VINCRISTINE; WARFARIN;

ANTITHROMBIN DEFICIENCY; ARTERY THROMBOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; GENE MUTATION; HUMAN; HYPERCOAGULABILITY; INCIDENCE; LOW DRUG DOSE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK ASSESSMENT; RISK FACTOR; THROMBOPHILIA; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

HUMANS; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; RISK FACTORS; THROMBOSIS;

EID: 78650984908     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.11.002     Document Type: Article

References (75)

1. Osman K., Comenzo R., Rajkumar S.V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001, 344:1951-1952.
2. Baz R., Li L., Kottke-Marchant K., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005, 80:1568-1574.
3. Rajkumar S.V., Blood E., Vesole D., Fonseca R., Greipp P.R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006, 24:431-436.
4. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
5. Facon T., Mary J.Y., Hulin C., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370:1209-1218.
6. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006, 367:825-831.
7. Hulin C., Facon T., Rodon P., et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009, 27:3664-3670.
8. Weber D., Rankin K., Gavino M., Delasalle K., Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003, 21:16-19.
9. Rajkumar S.V., Gertz M.A., Lacy M.Q., et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003, 17:775-779.
10. Cavo M., Zamagni E., Tosi P., et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004, 89:826-831.
11. Zonder J.A., Barlogie B., Durie B.G., McCoy J., Crowley J., Hussein M.A. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006, 108:403.
12. Richardson P.G., Schlossman R.L., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
13. Morgan G.J., Schey S.A., Wu P., et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007, 137:268-269.
14. Gay F., Hayman S.R., Lacy M.Q., et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 2010, 115:1343-1350.
15. Harousseau J.L., Attal M., Leleu X., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006, 91:1498-1505.
16. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009, 145:151-163.
17. Palumbo A., Bringhen S., Rossi D., et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010, Epub ahead of print.
18. Zangari M., Guerrero J., Cavallo F., Prasad H.K., Esseltine D., Fink L. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica 2008, 93:953-954.
19. Knight R., DeLap R.J., Zeldis J.B. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006, 354:2079-2080.
20. Rajkumar S.V., Jacobus S., Callander N.S., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11:29-37.
21. Falanga A., Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009, 27:4848-4857.
22. Kyle R.A., Rajkumar S.V. Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
23. Kristinsson S.Y., Fears T.R., Gridley G., et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008, 112:3582-3586.
24. Kristinsson S.Y., Pfeiffer R.M., Bjorkholm M., et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010, 115:4991-4998.
25. Libourel E.J., Sonneveld P., van der Holt B., de Maat M.P., Leebeek F.W. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 2010, Epub ahead of print.
26. Palumbo A., Rajkumar S.V., Dimopoulos M.A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008, 22:414-423.
27. Prevention of pulmonary embolismdeep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000, 355:1295-1302.
28. Geerts W.H., Bergqvist D., Pineo G.F., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133:381S-453S.
29. Turpie A.G., Levine M.N., Hirsh J., et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986, 315:925-929.
30. Ikhlaque N., Seshadri V., Kathula S., Baumann M.A. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 2006, 81:420-422.
31. Naess I.A., Christiansen S.C., Romundstad P., Cannegieter S.C., Rosendaal F.R., Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007, 5:692-699.
32. Sorensen H.T., Mellemkjaer L., Olsen J.H., Baron J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000, 343:1846-1850.
33. Zangari M., Barlogie B., Cavallo F., Bolejack V., Fink L., Tricot G. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul Fibrinolysis 2007, 18:595-598.
34. Zangari M., Tricot G., Polavaram L., et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 2010, 28:132-135.
35. Landgren O., Kyle R.A., Pfeiffer R.M., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113:5412-5417.
36. Muslimani A.A., Spiro T.P., Chaudhry A.A., Taylor H.C., Jaiyesimi I., Daw H.A. Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance. Clin Adv Hematol Oncol 2009, 7:827-832.
37. Cohen A.L., Sarid R. The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. Thromb Res 2010, 125:216-219.
38. Sallah S., Husain A., Wan J., Vos P., Nguyen N.P. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004, 15:1490-1494.
39. Srkalovic G., Cameron M.G., Rybicki L., Deitcher S.R., Kattke-Marchant K., Hussein M.A. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004, 101:558-566.
40. Gregersen H., Norgaard M., Severinsen M.T., Engebjerg M.C., Jensen P., Sorensen H.T. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. Eur J Haematol 2010, Epub ahead of print.
41. Berenson J.R., Anderson K.C., Audell R.A., et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 2010, Epub ahead of print.
42. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000, 160:809-815.
43. Prandoni P., Lensing A.W., Buller H.R., et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992, 327:1128-1133.
44. Landolfi R., Marchioli R., Kutti J., et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004, 350:114-124.
45. van Marion A.M., Auwerda J.J., Lisman T., et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 2008, 32:1078-1084.
46. Elice F., Fink L., Tricot G., Barlogie B., Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006, 134:399-405.
47. Zangari M., Elice F., Fink L., Tricot G. Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost 2007, 33:339-349.
48. Green D. Risk of future arterial cardiovascular events in patients with idiopathic venous thromboembolism. Hematology Am Soc Hematol Educ Program 2009, 259-266.
49. Dunkley S., Gaudry L. Thalidomide causes platelet activation, which can be abrogated by aspirin. J Thromb Haemost 2007, 5:1323-1325.
50. Fujita J., Mestre J.R., Zeldis J.B., Subbaramaiah K., Dannenberg A.J. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001, 7:3349-3355.
51. Johnson D.C., Corthals S., Ramos C., et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 2008, 112:4924-4934.
52. Avcu F., Ural A.U., Cetin T., Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res 2008, 121:567-571.
53. Sohn R.H., Deming C.B., Johns D.C., et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood 2005, 105:3910-3917.
54. Eroglu A., Sertkaya Karasoy D., Eroglu N., Akar N. Factor V 1691 G-A (Leiden) polymorphism and cancer-related venous thromboembolism: a meta-analysis of published studies. J BUON 2008, 13:61-64.
55. Decousus H., Moulin N., Quenet S., et al. Thrombophilia and risk of venous thrombosis in patients with cancer. Thromb Res 2007, 120(Suppl 2):S51-S61.
56. Coppens M., Reijnders J.H., Middeldorp S., Doggen C.J., Rosendaal F.R. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost 2008, 6:1474-1477.
57. Barlogie B., Desikan R., Eddlemon P., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001, 98:492-494.
58. Prince H.M., Mileshkin L., Roberts A., et al. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res 2005, 11:5504-5514.
59. Rajkumar S.V., Hayman S., Gertz M.A., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002, 20:4319-4323.
60. Palumbo A., Bertola A., Falco P., et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004, 5:318-324.
61. Offidani M., Corvatta L., Marconi M., et al. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J 2004, 5:312-317.
62. Wu P., Davies F.E., Horton C., et al. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide-vincristine-doxorubicin-methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma 2006, 47:2335-2338.
63. Zervas K., Dimopoulos M.A., Hatzicharissi E., et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004, 15:134-138.
64. Barlogie B., Tricot G., Anaissie E., et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006, 354:1021-1030.
65. Zangari M., Siegel E., Barlogie B., et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002, 100:1168-1171.
66. Wang M., Dimopoulos M.A., Chen C., et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008, 112:4445-4451.
67. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
68. Niesvizky R., Martinez-Banos D., Jalbrzikowski J., et al. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 2007, 48:2330-2337.
69. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005, 106:4050-4053.
70. Baz R., Walker E., Karam M.A., et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006, 17:1766-1771.
71. Minnema M.C., Breitkreutz I., Auwerda J.J., et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004, 18:2044-2046.
72. Klein U., Kosely F., Hillengass J., et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 2009, 88:67-71.
73. Wang M., Weber D.M., Delasalle K., Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005, 79:194-197.
74. Zangari M., Barlogie B., Anaissie E., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004, 126:715-721.
75. Offidani M., Corvatta L., Piersantelli M.N., et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006, 108:2159-2164.